New interim results from a six-month investigator-initiated trial (IIT) supported by Galderma, regarding the clinical sequencing of women in menopause, show the combination of Restylane Skinboosters and Sculptra drove meaningful improvements in skin barrier function, hydration and patient satisfaction, with the most pronounced gains in hydration – a critical factor for perimenopausal skin health – observed when using Restylane Skinboosters first1
New interim data from a separate IIT show the cellular composition of adipose (fat) tissue may be altered in patients experiencing aesthetic changes in the abdomen following medication-driven weight loss, offering a biological explanation for clinicianreported volume loss beyond weight reduction alone, and underscoring the importance of including regenerative aesthetic treatments as part of the patients’ weight loss journey2
These data reinforce Galderma’s continuous support of independent research, in order to deliver holistic, individualized and science-led solutions that address growing patient needs, such as aesthetic changes related to menopause and medication-driven weight loss

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today welcomes new data from two IITs, demonstrating the power of Sculptra – the first proven regenerative biostimulator – and the company’s versatile hyaluronic acid injectable Restylane range, in addressing the aesthetic changes associated with menopause and medication-driven weight loss, for the face and body.1-7 Data includes an analysis from a first-of-its-kind study evaluating optimal treatment sequencing to enhance women’s skin during menopause, and an evaluation of the cellular makeup of fat in the abdomen following medication-driven weight loss.1,2

The two IITs were designed and executed by Dr. Andreas Nikolis and Dr. Sabrina Fabi respectively.1,2 Galderma proudly supported the IITs as part of its longstanding commitment to understanding patients’ evolving needs and supporting to deliver the best solutions for optimal patient outcomes. This approach to evidence generation, informed by realworld needs, and enabled by the broadest Injectable Aesthetics portfolio in the industry, is designed to support advancements at every stage of the patient journey.

Menopause: Dualsequence study shows meaningful skin quality improvements and growing patient satisfaction with both Restylane Skinboosters and Sculptra

New interim results from a ninemonth clinical sequencing IIT of women in menopause conducted by Dr. Andreas Nikolis, both on the face and the décolletage, demonstrated that the combination of Restylane Skinboosters and Sculptra drove progressive and meaningful improvements in skin quality, with the most pronounced gains in hydration seen when using Restylane Skinboosters first.1 Hydration is a critical factor in menopausal skin health, as highlighted in an international survey of peri- and post-menopausal women as within their top five skin concerns for face and their number one concern for body.1,8,9

The data reinforce the relevance and synergistic effects of the two products, with Skinboosters driving faster extra-cellular matrix and elastin-associated effects to quickly deliver hydration and improvements in skin roughness, fine lines and other imperfections, and Sculptra delivering regenerative benefits across all three skin layers, helping to gradually restore volume, firmness, radiance and skin quality, and smoothing wrinkles and folds over time.1,3-7,10-12

Results showed that facial hydration and measures of skinbarrier function improved over time in both groups, and the improvements were mirrored by patientreported outcomes, with satisfaction scores rising consistently across the study and reaching high levels by Month 6.1 Together, these data show that both treatment sequences contribute to measurable improvements in skin health in women during menopause, and they provide insight into how the treatment protocol may be optimized for this specific patient group.1

“Menopause is associated with a distinct and often under-recognized set of skin changes, including dryness, barrier dysfunction, and progressive declines in skin quality. This first-of-its-kind clinical study is helping address an important unmet need by generating objective data in a population that has historically been overlooked in aesthetic research. The interim findings are highly encouraging, demonstrating meaningful improvements in skin hydration and collagen-related skin quality over time. Equally important, these measurable clinical benefits are mirrored by rising patient satisfaction throughout the study. For clinicians, these early results offer valuable evidence-based insight into how we can better support aging menopausal patients with treatment strategies that are tailored to the biologic changes of this stage of life.”   DR. ANDREAS NIKOLIS STUDY LEAD INVESTIGATOR AND BOARD-CERTIFIED PLASTIC SURGEON MONTREAL, CANADA